BioPoint Inc

BioPoint Inc. is a US-based Life Sciences consulting firm focused in the areas of Drug Safety.

is a US based life sciences consulting organization focused in the areas of Drug Safety, Health Economic

09/08/2025

AI is fundamentally changing healthcare, accelerating drug development and improving our ability to detect and treat diseases. https://www.biopharmadive.com/spons/harnessing-the-power-of-ai-to-detect-attr-cm/758919/

From accelerating drug discovery to improving disease detection, AI is transforming the way we understand and manage health.

09/05/2025

Founded by the ex-CEO of Hi-Bio and supported by prominent investors, this new venture has acquired the rights to a drug from Hengrui. The company believes this drug offers significant advantages over Bristol Myers' Camzyos and other comparable therapies. https://www.biopharmadive.com/news/braveheart-hengrui-hypertrophic-cardiomyopathy-china-licensing-deal/759365/

Led by the former CEO of Hi-Bio and backed by notable investors, the startup licensed from Hengrui a drug it claims is superior to Bristol Myers' Camzyos as well as other, similar medicines.

09/04/2025

Leveraging a $300 million investment this year, Enveda Biosciences is pioneering new drug discovery approaches to create treatments for conditions such as atopic dermatitis and asthma. https://www.biopharmadive.com/news/enveda-series-d-immune-obesity-dolsten-board/759080/

Enveda Biosciences has raised $300 million over the last year to make drugs to treat atopic dermatitis, asthma and more.

09/03/2025

Leveraging the expertise of Loxo founder Josh Bilenker and former Novartis executive Jeff Engelman, the biotech has advanced three cancer drug candidates into Phase 1, signaling promising progress in the fight against cancer. https://www.biopharmadive.com/news/secretive-startup-treeline-unveils-first-clinical-candidates-200m-in-new/759103/

The biotech started by Loxo founder Josh Bilenker and former Novartis executive Jeff Engelman has advanced three cancer drugs to Phase 1 trials.

09/02/2025

Amgen is expanding its presence in Thousand Oaks, California, with the construction of a new "science and innovation center" at its headquarters. In related news, Wayrilz has achieved a significant milestone, becoming the first BTK blocker approved for the treatment of immune thrombocytopenia. https://www.biopharmadive.com/news/amgen-new-center-replimune-fda-meeting-sanofi-wayrilz/758944/

The new "science and innovation center" will be built at Amgen's headquarters in Thousand Oaks, California. Elsewhere, Wayrilz became the first BTK blocker cleared for immune thrombocytopenia.

08/28/2025

Verzenio improved survival in patients with a common type of early breast cancer compared to standard hormone therapy. https://www.biopharmadive.com/news/lilly-verzenio-survival-data-breast-cancer-monarche-study/758751/

Treatment with Verzenio helped people with a common type of early breast cancer liver longer than those given standard hormone therapy.

08/27/2025

The St. Louis-based biotech is planning to submit an application for its leukemia and lymphoma therapy in 2027, pending favorable outcomes from its current clinical trial. https://www.biopharmadive.com/news/wugen-funding-car-t-allogeneic-off-the-shelf/758726/

The St. Louis-based biotech hopes to submit an application for its leukemia and lymphoma therapy in 2027, if all goes well in an ongoing trial.

08/26/2025

Orforglipron induced weight loss in people with diabetes and obesity that was similar to weight loss seen in non-diabetic populations in earlier studies. https://www.biopharmadive.com/news/lilly-glp-1-orforglipron-fda-submission-obesity-diabetes/758608/

In people with diabetes and obesity, orforglipron led to weight loss near what people without diabetes experienced in prior testing.

08/22/2025

Dawnzera marks the third new treatment approved by U.S. regulators this year for this rare genetic condition, and the second developed and brought to market entirely by Ionis. https://www.biopharmadive.com/news/ionis-donidalorsen-dawnzera-hereditary-angioedema-approval-fda/758195/

Dawnzera is the third medicine cleared by U.S. regulators this year for the rare genetic condition. Ionis set its list price at $57,462 per dose.

08/21/2025

Gilead's acquisition provides access to technology for in vivo CAR-T cell modification, potentially expanding treatment options. https://www.biopharmadive.com/news/gilead-interius-acquire-in-vivo-cell-therapy/758266/

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could potentially widen access to CAR-T treatment.

08/20/2025

After a participant death earlier this year, the company will continue the trial with a lower dose and a modified pre-treatment plan. https://www.biopharmadive.com/news/rocket-fda-lift-hold-danon-gene-therapy-trial/758117/

The company plans to continue with a lower dose and a change in the pre-treatment regimen after a trial participant died earlier this year.

08/19/2025

Negative trial results, specifically higher discontinuation rates, led to a substantial decline in Viking's market value. https://www.biopharmadive.com/news/viking-oral-obesity-drug-results-study-discontinuationsdata-dropout/758019/

The company’s market value was nearly cut in half following trial results showing higher rates of treatment discontinuations among people receiving Viking’s drug.

Address

13 Centennial Drive Ste. 1
Peabody, MA
01960

Website

http://www.biopointinc.com/

Alerts

Be the first to know and let us send you an email when BioPoint Inc posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to BioPoint Inc:

Shortcuts

Want your practice to be the top-listed Clinic in Peabody?